NK cell therapy after hematopoietic stem cell transplantation: can we improve anti-tumor effect?

about

Natural Killer Cells: Development, Maturation, and Clinical Utilization

P2860

Q58785734-F12C51FA-55D6-4D32-8288-F8DA3606B19E

P2860

NK cell therapy after hematopoietic stem cell transplantation: can we improve anti-tumor effect?

Item

http://www.wikidata.org/entity/Q47570438

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

NK cell therapy after hematopo ...... we improve anti-tumor effect?

@en

NK cell therapy after hematopo ...... we improve anti-tumor effect?

@nl

type

Item

label

NK cell therapy after hematopo ...... we improve anti-tumor effect?

@en

NK cell therapy after hematopo ...... we improve anti-tumor effect?

@nl

prefLabel

NK cell therapy after hematopo ...... we improve anti-tumor effect?

@en

NK cell therapy after hematopo ...... we improve anti-tumor effect?

@nl

P1476

NK cell therapy after hematopo ...... we improve anti-tumor effect?

@en

P2093

Catharina H M J Van Elssen

http://www.w3.org/2001/XMLSchema#string

Stefan O Ciurea

http://www.w3.org/2001/XMLSchema#string

P2860

Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation

Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation

Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation

Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-Hodgkin lymphomas

"Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell.

Outcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one human leukocyte antigen mismatched related donors using HLA typing at 10 loci.

P2888

s12185-017-2379-x

P304

151-156

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S12185-017-2379-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29196968

http://www.w3.org/2001/XMLSchema#string

NK cell therapy after hematopoietic stem cell transplantation: can we improve anti-tumor effect?

about

P2860

P2860

NK cell therapy after hematopoietic stem cell transplantation: can we improve anti-tumor effect?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698